<DOC>
	<DOCNO>NCT00019227</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody plus pentetic acid calcium patient leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 daclizumab ( 90Y daclizumab ) combine pentetic acid calcium adult Tac-expressing T-cell leukemia . - Determine therapeutic efficacy toxicity regimen patient . - Monitor patient treat regimen circulate infuse antibody ( free label ) serum concentration soluble interleukin-2 receptor . - Evaluate , preliminary manner , immunogenicity daclizumab . - Determine effect 90Y daclizumab various component circulate cellular immune system . - Determine whether additional urinary excretion yttrium Y 90 compare observe previously patient treat without pentetic acid calcium . OUTLINE : This dose escalation study yttrium Y 90 daclizumab ( 90Y daclizumab ) . Patients receive 90Y daclizumab IV 2 hour day 1 fix dose pentetic acid calcium IV 5 hour 3 day . Treatment repeat every 6 week maximum 9 course absence disease progression circulate antibody humanize anti-Tac . Cohorts 3-6 patient receive escalate dos 90Y daclizumab maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Additional patient treat MTD . Patients follow 4-6 week . PROJECTED ACCRUAL : Up 15 patient accrued phase I portion study . A total 30 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adult Tcell leukemia lymphoma ( ATL ) stage Tac expression malignant cell confirm one following : At least 10 % peripheral blood , lymph node , dermal malignant cell reactive antiTac immunofluorescent stain Soluble interleukin2 receptor level great 1,000 U/mL ( normal geometric mean = 235 ; 95 % confidence interval = 112502 U/mL ) Measurable disease require More 10 % ( i.e. , strongly Tacexpressing ) abnormal cell peripheral blood consider measurable disease All stag Tacexpressing adult Tcell leukemia eligible Smoldering ATL patient eligible symptom sit involvement ATL medical indication treat Smoldering ATL , define : Lymphocyte count less 4,000/mm^3 Less 5 % abnormal lymphocytes morphologic exam peripheral blood No hypercalcemia Lactate dehydrogenase great 1.5 time normal No lymphadenopathy No involvement extranodal organs except skin lung No malignant pleural effusion ascites No symptomatic CNS disease due ATL Concurrent diagnosis tropical spastic paraparesis allow No detectable level ( i.e. , great 250 ng/mL ) antibody study drug assess ELISA PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Greater 2 month Hematopoietic : Absolute granulocyte count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL ( unless directly due ATL ) AST/ALT le 2.5 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 35 mL/min Cardiovascular : No clinical cardiac failure Pulmonary : No symptomatic pulmonary dysfunction unless due underlying malignancy Other : HIV negative Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior cytotoxic chemotherapy Endocrine therapy Concurrent corticosteroid allow Radiotherapy Not specify Surgery Not specify Other Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>